SAILIFE / Q4-FY26 / risks

Keep the risk register visible.

Sai Life Sciences · Material risks, their source context, and severity in the latest available quarter.

Research layer active

ConCallIQ research layer

Signal, with the source still visible.

Use the controls below to narrow the view, then follow the evidence into the next layer of context.

PositiveQ4-FY26 · 2026-05-01Back to quarter ↗

Risk intelligence

Material risks this quarter

Geopolitical cost headwinds

Input cost inflation and logistics disruptions from geopolitical tensions may not be fully recovered from customers in a timely manner, pressuring margins.

medium

Execution risk from rapid capex scale-up

Doubling capex to ₹1,100-1,300 crore could strain organizational capability and lead to inefficiencies, as flagged by an analyst question on execution fragility.

high

New modalities revenue decline

Revenue from new modalities fell from 7% to 4% of total, indicating lumpiness in clinical-stage campaigns and potential competitive pressure.

medium

Customer concentration risk

Top 10 customers contribute 54% of revenue; loss of any key customer could materially impact results.

medium